A continuously increasing number of gene therapies are under development and are being approved and marketed for use in patients, resulting in an ever-increasing demand for pharmaceutical grade DNA
The conventional, fermentation based, DNA production methods offer poor yields and are held back due to complex purification processes. The final product is therefore expensive, and the processes are difficult and costly to scale
Furthermore, the DNA product (plasmids) created by fermentation-based approaches contain both the human DNA of interest as well as contaminant bacterial DNA which is not only immunogenic but also typically contains antibiotic resistant genes. Widespread clinical use of such type of DNA may therefore pose significant concern
For a breakthrough of gene therapies and DNA vaccines, large amounts of pharmaceutical-grade DNA are needed
4basebio develops highly effective, scalable, faster and safer, bacterial free manufacturing processes for the synthetic production of pharmaceutical grade hairpinDNA (hpDNA)
4basebio AG is the new name of Expedeon AG; its ticker symbol has changed to 4BSB from EXNN.
4basebio AG ist der neue Name der Expedeon AG; Das Tickersymbol wurde von EXNN auf 4BSB geändert.